A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease
- 1The Ohio State University College of Medicine, Columbus, OH USA
- 2Department of Dermatology, Wexner Medical Center, Ohio State University, Columbus, OH USA
Abstract
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following hematopoietic stem cell transplant, with the skin being one of the most common and persistently affected organs in acute and chronic forms of the disease. Topical corticosteroids and supportive dermatologic care are foundational in mild cutaneous disease; however, moderate-to-severe disease frequently requires systemic corticosteroid therapy. Despite systemic corticosteroids being first-line therapy in moderate-to-severe disease, up to 60% of patients will develop steroid-refractory or steroid-resistant disease, emphasizing the need for alternative therapies. Recent advances in GVHD management have led to the introduction of targeted systemic agents, such as ruxolitinib, belumosudil, axatilimab, ibrutinib, and abatacept, each addressing different pathways implicated in disease pathogenesis and leading to incorporation into disease management based on established algorithms or select clinical contexts. Additionally, local immunomodulatory therapies, such as topical ruxolitinib, phototherapies, and extracorporeal photopheresis, can be utilized as adjunctive therapies for persistent or localized cutaneous disease. Cellular therapies, specifically mesenchymal stromal cells and regulatory T cells (Treg), are emerging therapies with promising potential in modulating the immune response and improving clinical outcomes. This review summarizes the current standards of care and recent therapeutic advances in the management of cutaneous GVHD, focusing on evidence-based therapies and skin-specific outcomes.
Related
- Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
- Emerging gene therapies in the treatment of recessive dystrophic epidermolysis bullosa: a systematic review
- Efficacy of combined therapies on degenerative joint disease of the temporomandibular joint: A systematic review and meta-analysis
- Comparative efficacy and safety of targeted disease-modifying therapies in adults with primary IgA nephropathy: a systematic review and network meta-analysis
- Peripheral Neuropathy in Parkinson’s Disease Treated with Device-Assisted Therapies: How Often It Is Reported Depends on How It Is Sought. A Systematic Review and Meta-Analysis
BibTeX
@article{khuhro2026review,
title = {{A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease}},
author = {Aliza Khuhro and Christina Isckarus and Esha Chadha and Brittany Dulmage},
journal = {Dermatology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13555-026-01919-3},
url = {https://doi.org/10.1007/s13555-026-01919-3},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease
AU - Aliza Khuhro
AU - Christina Isckarus
AU - Esha Chadha
AU - Brittany Dulmage
PY - 2026
DA - 2026/09/01
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01919-3
UR - https://doi.org/10.1007/s13555-026-01919-3
AB - Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following hematopoietic stem cell transplant, with the skin being one of the most common and persistently affected organs in acute and chronic forms of the disease. Topical corticosteroids and supportive dermatologic care are foundational in mild cutaneous disease; however, moderate-to-severe disease frequently requires systemic corticosteroid therapy. Despite systemic corticosteroids being first-line therapy in moderate-to-severe disease, up to 60% of patients will develop steroid-refractory or steroid-resistant disease, emphasizing the need for alternative therapies. Recent advances in GVHD management have led to the introduction of targeted systemic agents, such as ruxolitinib, belumosudil, axatilimab, ibrutinib, and abatacept, each addressing different pathways implicated in disease pathogenesis and leading to incorporation into disease management based on established algorithms or select clinical contexts. Additionally, local immunomodulatory therapies, such as topical ruxolitinib, phototherapies, and extracorporeal photopheresis, can be utilized as adjunctive therapies for persistent or localized cutaneous disease. Cellular therapies, specifically mesenchymal stromal cells and regulatory T cells (Treg), are emerging therapies with promising potential in modulating the immune response and improving clinical outcomes. This review summarizes the current standards of care and recent therapeutic advances in the management of cutaneous GVHD, focusing on evidence-based therapies and skin-specific outcomes.
SN - 2193-8210
SN - 2190-9172
ER -